

Life sciences

DISRUPTIVE TECHNOLOGY FOR THE PRODUCTION OF PLASMA DERIVED MEDICINES (ALBUMIN AND IMMUNOGLOBULIN)

Pharmacist



Company's INFORMATION

LifeFactors is a business group founded in 2017, which, based on a new technology, obtains blood products from recovered plasma.

It provides life-saving therapies for people suffering from serious diseases that are of high impact (cost and quality of life). They are committed to proposing solutions for more sustainable healthcare in developing countries.

It has operations in Colombia, Mexico, Ecuador and Brazil.



Initial investment
Capex USD 30 Millions

* TRM: 4.437



Investment mechanism
Equity / Mix



Quantifiable impact
50% higher immunoglobulin productivity and 30% higher in Albumin. 5 times lower CAPEX for the construction of processing plants.

Investment PROPOSAL

The project is designed to be executed during the years 2023-2029 and includes:

Concluding the construction of the productive capacity of 250,000 liters of plasma per year, which is 50% complete.

Expand the plasma acquisition capacity to achieve a supply of 500,000 liters per year, which will be allocated to the own production plant and to third-party plants with processing capacity.

The quantities and markets of third-party portfolios will be expanded, to reach Brazil, Mexico, Ecuador, and Paraguay with sales of USD 120 Millions



<https://lifefactors.com.co/>



LifeFactors



lifefactors